Seven research firms currently cover Integra LifeSciences, assigning three sell ratings, two hold ratings and two buy ratings. Over the past quarter, Weiss Ratings maintained its sell assessment, while Wall Street Zen upgraded to a buy. JPMorgan Chase & Co. and Truist Financial both reiterated underweight/hold views with adjustments to their earnings outlook, and Citigroup lowered its outlook to a sell stance. This mix of opinions reflects a cautious market sentiment and underscores the importance for investors to monitor shifts in analyst conviction.

In its latest quarter, Integra reported EPS of $0.54, surpassing the consensus expectation of $0.43. Revenue reached $402.1 million, up 5.6% year-over-year but slightly below the $414.3 million forecast. The company registered a negative net margin of 30.15% alongside a 14.06% return on equity. Looking ahead, management set Q4 EPS guidance at a range of 0.79 to 0.84 and full-year guidance of 2.19 to 2.24, while analysts collectively anticipate adjusted EPS of approximately 2.45 for the current fiscal year.

Director Jeffrey A. Graves acquired an additional 9,000 shares in early November, boosting his total holding to over 41,000 shares—a 28.1% increase in ownership. This transaction, disclosed via SEC filing, signals continued insider confidence in the company’s strategic direction and potential for long-term value creation.

Institutional investors hold 84.8% of Integra’s shares. In the first quarter, Mirae Asset Global ETFS raised its stake by 5.1%, adding 1,975 shares, while Goldman Sachs increased its position by 2.2%, acquiring an additional 35,790 shares. UBS Asset Management boosted its holdings by 23%, adding 45,693 shares. Meanwhile, Dynamic Technology Lab and STRS Ohio initiated new positions, reflecting renewed institutional interest in Integra’s med-tech portfolio.